CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.

Interestingly, tumor-infiltrating CD8+ T effs from the CD25-ADC-treated groups (either alone or in combination with anti-PD-1) had significantly higher activation (p<0.01, figure 5B , top panels) and proliferation rates compared with CD8+ T effs from the control groups on day 11 (p<0.01, figure 5B , middle panels) and their interferon-γ production peaked on day 8, although the increase did not reach statistical significance compared with the controls ( figure 5B , bottom panels).

also in 111,027 other papers